article thumbnail

QMS market to value nearly $4b by 2030

European Pharmaceutical Review

According to the research, the pharmaceutical quality management systems market is projected to reach $3.97 billion by 2030. Some pharmaceutical companies are increasing their R&D spending to increase product numbers. Also noted in the report was the shift towards cloud-based systems.

article thumbnail

PAN-TB’s Phase II trials take a shot at shorter TB regimens

Pharmaceutical Technology

Earlier this month, the World Health Organisation (WHO) released a new guidance document with a strategic plan to counter TB on a national level. This guidance is in line with the WHO’s End TB Strategy, which aims for an 80% fall in worldwide TB incidence and a 90% decrease in TB deaths by 2030, compared with 2015.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sustainability: Corporate Ambition, Governance, & Accelerated Delivery

ISPE

Transforming Our World: The 2030 Agenda for Sustainable Development.” A collaborative mindset must prevail between pharmaceutical companies, suppliers, and regulators and include strategic partnerships that go beyond the pharmaceutical sector so we can move together to a more sustainable future. 1 United Nations.

article thumbnail

A New Regulatory Approach to Drive Sustainable Medicines

ISPE

According to the proposal, all packaging shall be designed for recycling by 1 January 2030 and be recycled at scale by 1 January 2035. A pharmaceutical quality system (PQS) is a management system used to direct and control a pharmaceutical company with regard to quality. Press Release. 30 November 2022. 27 January 2022.

article thumbnail

The rise and rise of ESG in the pharmaceutical sector – is a zero-waste supply?chain possible?? 

Pharmaceutical Technology

AstraZeneca has announced its supply chain will be carbon negative by 2030. Of the world’s 20 largest pharmaceutical companies, 17 have launched programmes tailored towards increasing medication access in low- and middle-income countries – up from just eight in 2010. A similar theme is evident in company filings.